Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PRGO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPerrigo completes €305.6M sale of Dermacosmetics Business to Karo Healthcare
Filed April 30, 2026 · Period ending April 30, 2026 · ~1 min read
Key Changes
-
high
Perrigo received €305.6 million in cash at closing for its Dermacosmetics Business in Northern Europe, Netherlands and Poland, including €5.6 million in net working capital adjustments. Transaction closes strategic divestiture announced in July 2025.
Item 1.01 view on EDGAR → -
medium
Company may receive up to €27 million in additional earnout payments over three years if the divested business hits undisclosed performance targets, adding potential upside to the base purchase price.
Item 1.01 view on EDGAR → -
low
Original buyer Kairos Bidco AB (KKR-managed) assigned all rights to affiliate Karo Healthcare AB prior to closing. This structural change does not affect transaction terms or economics for Perrigo.
Item 1.01 view on EDGAR →
Summary
Perrigo closed the sale of its Dermacosmetics Business on April 30, 2026, receiving €305.6 million in cash from Karo Healthcare. The divestiture, first announced in July 2025, removes a non-core European business segment and provides immediate liquidity.
The company structured the deal with a potential €27 million earnout tied to the business's performance over the next three years, creating upside if targets are met. For retail investors, this transaction represents portfolio simplification and debt reduction capacity. The €305.6 million proceeds give Perrigo financial flexibility to pay down debt, fund core operations, or pursue strategic investments.
The earnout provision means total consideration could reach €332.6 million if performance thresholds are achieved. Watch for Perrigo's next quarterly earnings to see how management deploys the proceeds and whether guidance changes reflect the smaller business footprint. The earnout payments, if earned, would flow in over 2027-2029 and could provide modest additional cash.
Section-by-Section Diff
Event · Item 2.01 — Completion of Acquisition or Disposition of Assets
Perrigo completed sale of Dermacosmetics Business to Karo Healthcare for €305.6M cash plus potential €27M earnout.
Added in current filing · verify on EDGAR →
In addition, the Company may be entitled to additional contingent cash consideration of up to €27.0 million upon achievement of certain performance thresholds by the Dermacosmetics Business over a three-year period.
Beyond the upfront cash payment, Perrigo may receive up to an additional €27.0 million over three years if the divested Dermacosmetics Business achieves certain undisclosed performance targets. This earnout structure ties a portion of the total consideration to future business performance.
Event · Item 7.01 — Regulation FD Disclosure
Perrigo announced completion of an unspecified Transaction via press release on April 30, 2026.
Added in current filing · verify on EDGAR →
On April 30, 2026, Perrigo issued a press release announcing the completion of the Transaction, a copy of which is attached hereto as Exhibit 99.1.
Perrigo disclosed that it completed a transaction referred to as 'the Transaction' on April 30, 2026. The 8-K does not specify what the transaction entails—details are contained in the attached press release (Exhibit 99.1), which is not included in this filing body. Without the exhibit text, the nature, parties, and financial impact of the transaction remain unclear.
Event · Item 9.01 — Financial Statements and Exhibits
Perrigo issued a press release on April 30, 2026, related to a previously disclosed divestiture transaction with Kairos Bidco AB.
Added in current filing · verify on EDGAR →
Press Release issued by Perrigo Company plc on April 30, 2026 furnished solely pursuant to Item 7.01 of Form 8-K.
Perrigo issued a press release on April 30, 2026, furnished under Item 7.01 of Form 8-K. The 8-K references a previously disclosed Master Sale and Purchase Agreement dated July 13, 2025, with Kairos Bidco AB for a divestiture. The forward-looking statements section discusses anticipated benefits including portfolio focus, financial flexibility, debt reduction, and contingent consideration tied to future net sales performance of the disposed business.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify